2025年5月31日現在
| Publication year | WJOG Trial No. | Trial name | Cancer group | Title | First Author | Journal | pubmed |
|---|---|---|---|---|---|---|---|
| 2025 | WJOG18524G | RAINBIRD | GI | WJOG18524G: a single-arm phase II study evaluating bemarituzumab combined with ramucirumab and paclitaxel in fibroblast growth factor receptor 2b (FGFR2b)-positive advanced gastric or gastroesophageal junction cancer (RAINBIRD) | Keitaro Shimozaki | ESMO Gastrointest Oncol | https://pubmed.ncbi.nlm.nih.gov/41647978/ |
| 2025 | WJOG16322G | GI | A multicenter Phase II study of mFOLFOX6 plus nivolumab for gastric cancer with severe peritoneal metastases: WJOG16322G | Munehiro Wakabayashi | Future Oncol | https://pubmed.ncbi.nlm.nih.gov/40476844/ | |
| 2025 | WJOG15721B | RealisE | Breast | Risk factors for early recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a retrospective cohort study in Japan (WJOG15721B) | Rurina Watanuki | Breast Cancer | https://pubmed.ncbi.nlm.nih.gov/40208504/ |
| 2025 | WJOG14320B | ERICA | Breast | Olanzapine for nausea and vomiting in people with breast cancer treated with trastuzumab deruxtecan: plain language summary of the ERICA study | Hitomi Sakai | Future Oncol | https://pubmed.ncbi.nlm.nih.gov/41132084/ |
| 2025 | WJOG13520L | REBORN | Thoracic | Durvalumab plus irinotecan +cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L) | Motoko Tachihara | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/40602202/ |
| 2025 | WJOG13420G | RAM-NEC | GI | Ramucirumab-containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum-based chemotherapy: a multicenter observational retrospective study (WJOG13420G) | Yuki Matsubara | Int J Cancer | https://pubmed.ncbi.nlm.nih.gov/40699213/ |
| 2025 | WJOG13320G | NO LIMIT | GI | Phase II Study (NO LIMIT, WJOG13320G) of First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability–High Advanced Gastric or Esophagogastric Junction Cancer | Hisato Kawakami | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/40378356/ |
| 2025 | WJOG12119L | SQUAT | Thoracic | Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage III N2 Non-Small Cell Lung Cancer: Primary Results from SQUAT trial (WJOG 12119L) | Akira Hamada | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/40216327/ |
| 2025 | WJOG12019L | Thoracic | Intensity-Modulated Radiotherapy for Locally Advanced Lung Cancer in the Immunotherapy Era: A Prospective Study WJOG12019L | Hideyuki Harada | JTO Clin Res Rep | https://pubmed.ncbi.nlm.nih.gov/40336674/ | |
| 2025 | WJOG11218LTR | Thoracic | Serum VEGF-A as a biomarker for the addition of bevacizumab to chemoimmunotherapy in metastatic NSCLC | Kentaro Tanaka | Nat Commun | https://pubmed.ncbi.nlm.nih.gov/40121197/ | |
| 2025 | WJOG10617G | P-SELECT | GI | Solvent-based or nab-paclitaxel plus ramucirumab for pretreated gastric cancer with peritoneal dissemination and prespecified biomarker analysis (P-SELECT/WJOG10617G): a randomised phase 2 trial in Japan | Kenro Hirata | EClinicalMedicine | https://pubmed.ncbi.nlm.nih.gov/41660367/ |
| 2025 | WJOG10417GTR | GI | IL33-ST2 axis is a predictive biomarker for anti-PD1 therapeutic efficacy in advanced gastric cancer | Chie Kudo-Saito | J Transl Med | https://pubmed.ncbi.nlm.nih.gov/41107859/ | |
| 2025 | WJOG10417GTR | GI | Peripheral SNCA+ cells as a poor prognostic factor for nivolumab therapy in advanced gastric cancer | Chie Kudo-Saito | Discov Oncol | https://pubmed.ncbi.nlm.nih.gov/41123746/ | |
| 2025 | WJOG10417GTR | GI | The FSTL1-DIP2A axis is a distinctive biomarker to predict anti-PD1 therapeutic efficacy in advanced gastric cancer | Chie Kudo-Saito | Cancer Immunol Immunother | https://pubmed.ncbi.nlm.nih.gov/41251805/ | |
| 2025 | WJOG10317L | EMERALD | Thoracic | Phase III study of ramucirumab plus docetaxel versus atezolizumab for previously treated PD-L1 low or negative advanced non-small-cell lung cancer: WJOG10317L study | Yoshitaka Zenke | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/40602204/ |
| 2025 | JCOG1404/WJOG8214LA1 | Thoracic | Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutations | Eiji Iwama | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/40974872/ | |
| 2024 | WJOG9717L | Thoracic | Final analysis data and exploratory biomarker analysis of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small-cell lung cancer harboring EGFRmutations: the WJOG9717L study | Hirotsugu Kenmotsu | JTO Clin Res Rep | https://pubmed.ncbi.nlm.nih.gov/39399795/ | |
| 2024 | WJOG6410LTR | Thoracic | NOTCH1 and CREBBP co-mutations negatively affect the benefit of adjuvant therapy in completely resected EGFR-mutated NSCLC: translational research of phase III IMPACT study | Satoshi Ikeda | Mol Oncol | https://pubmed.ncbi.nlm.nih.gov/37864465/ | |
| 2024 | WJOG5810G | GI | A phase 2 study of adjuvant chemotherapy with 5-fluorouracil/leucovorin and oxaliplatin after lung metastasectomy for colorectal cancer (WJOG5810G) | Nozomu Machida | Cancer | https://pubmed.ncbi.nlm.nih.gov/40130723/ | |
| 2024 | WJOG16923L | Thoracic | A Multi-Institutional, Randomized, Phase III Trial Comparing Anatomical Segmentectomy and Lobectomy for Clinical Stage IA3 Pure-Solid Non-Small-Cell Lung Cancer: West Japan Oncology Group Study WJOG16923L (STEP UP Trial) | Atsushi Kamigaichi | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/38360496/ | |
| 2024 | WJOG16422L | JIMPACT | Thoracic | Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies | Hiroaki Akamatsu | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/39938189/ |
| 2024 | WJOG14320B | ERICA | Breast | A randomized, double-blind, placebo-controlled phase II study of olanzapine-based prophylactic antiemetic therapy for delayed and persistent nausea and vomiting in patients with HER2-positive or HER2-low breast cancer treated with trastuzumab deruxtecan: ERICA study (WJOG14320B) | Hitomi Sakai | Ann Oncol | https://pubmed.ncbi.nlm.nih.gov/39284382/ |
| 2024 | WJOG13320GPS | GI | Prevalence and clinicopathological features of microsatellite instability-high metastatic or recurrent gastric and esophagogastric junction cancer: WJOG13320GPS | Azusa Komori | Gastric Cancer | https://pubmed.ncbi.nlm.nih.gov/39738793/ | |
| 2024 | WJOG12219LTR | Thoracic | The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma | Hiroaki Kanemura | JTO Clin Res Rep | https://pubmed.ncbi.nlm.nih.gov/38651033/ | |
| 2024 | WJOG11919L | ABRAID | Thoracic | Prospective observational study to explore genes and proteins predicting efficacy and safety of brigatinib for ALK-gene rearranged non-small-cell lung cancer: study protocol for ABRAID study (WJOG11919L) | Yuichi Ozawa | Ther Adv Med Oncol | https://pubmed.ncbi.nlm.nih.gov/38282663/ |
| 2024 | WJOG11018G | GI | A Phase II Study of FOLFIRI Plus Ziv-Aflibercept After Trifluridine/Tipiracil Plus Bevacizumab in Patients with Metastatic Colorectal Cancer: WJOG 11018G | Toshihiko Matsumoto | Target Oncol | https://pubmed.ncbi.nlm.nih.gov/38427280/ | |
| 2024 | WJOG10417GTR | GI | Myeloid subsets impede the efficacy of anti-PD1 therapy in patients with advanced gastric cancer (WJOG10417GTR study) | Hirokazu Shojii | J Immunother Cancer | https://pubmed.ncbi.nlm.nih.gov/39489543/ | |
| 2024 | JCOG1404/WJOG8214L | AGAIN | Thoracic | Randomized Phase III Study of EGFR Tyrosine Kinase Inhibitor and Intercalated Platinum-doublet Chemotherapy for Non-small Cell Lung Cancer Harboring EGFR Mutation | Shintaro Kanda | Clin Cancer Res | https://pubmed.ncbi.nlm.nih.gov/40162917/ |
| 2023 | WJOGG11619L | DOLPHIN | Thoracic | Durvalumab Plus Concurrent Radiotherapy for Treatment of Locally Advanced Non–Small Cell Lung Cancer. The DOLPHIN Phase 2 Nonrandomized Controlled Trial. | Motko Tachihara | JAMA Oncol | https://pubmed.ncbi.nlm.nih.gov/37676681/ |
| 2023 | WJOG9616L | Thoracic | Nivolumab Retreatment in Non–Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L) | Hiroaki Akamatsu | Clin Cancer Res | https://pubmed.ncbi.nlm.nih.gov/35762926/ | |
| 2023 | WJOG9416L | DRAGON | Thoracic | Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L) | Motoko Tachihara | JTO Clin Res Rep | https://pubmed.ncbi.nlm.nih.gov/37822699/ |
| 2023 | WJOG8916G | GI | A multicenter phase II trial of trifluridine/tipiracil in combination with cetuximab rechallenge in patients with RAS wild-type metastatic colorectal cancer refractory to prior anti-EGFR antibodies： the WJOG8916G trial | Naoki Izawa | Target Oncol | https://pubmed.ncbi.nlm.nih.gov/37148491/ | |
| 2023 | WJOG5108LFS | Thoracic | Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS) | Nobuyuki Katakami | Int J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/36414827/ | |
| 2023 | WJOG15822G | RETRIEVE | GI | Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM)versus trifluridine/tipiracil for previously treated patients with advanced gastricor esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G) | Naoki Takahashi | BMC Cancer | https://pubmed.ncbi.nlm.nih.gov/37543568/ |
| 2023 | WJOG15421L | REVEAL | Thoracic | Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non–Small Cell Lung Cancer | Tomohiro Sakamoto | JAMA Netw Open | https://pubmed.ncbi.nlm.nih.gov/38100106/ |
| 2023 | WJOG14720L | B-DASH | Thoracic | Randomized, open-label phase II study of brigatinib and carboplatin plus pemetrexed and brigatinib alone for chemotherapy-naive patients with ALK-rearranged non-squamous non-small cell lung cancer: treatment rationale and protocol design of the B-DASH study (WJOG 14720 L) | Kazushige Wakuda | BMC Cancer | https://pubmed.ncbi.nlm.nih.gov/37749521/ |
| 2023 | WJOG14520G | GI | Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G) | Yosuke Kito | Oncologist | https://pubmed.ncbi.nlm.nih.gov/37950903/ | |
| 2023 | WJOG14320B | ERICA | Breast | Multicentre, randomised, double-blind, placebo-controlled phase II study of prophylactic olanzapine for patients with metastatic breast cancer receiving T-DXd treatment: protocol for the ERICA study (WJOG14320B) | Hitomi Sakai | BMJ Open | https://pubmed.ncbi.nlm.nih.gov/37012013/ |
| 2023 | WJOG13119L | Thoracic | Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer | Takeshi Masuda | Sci Rep | https://pubmed.ncbi.nlm.nih.gov/37957228/ | |
| 2023 | WJOG12319LTR | Thoracic | Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant Chemotherapy | Junko Tanizaki | JTO Clin Res Rep | https://pubmed.ncbi.nlm.nih.gov/38029041/ | |
| 2023 | WJOG11518L | SUBMARINE | Thoracic | Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE) | Koji Haratani | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/37364849/ |
| 2023 | WJOG11518L | SUBMARINE | Thoracic | Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer | Koji Haratani | Br J Cancer | https://pubmed.ncbi.nlm.nih.gov/38519705/ |
| 2023 | WJOG11418B | NEWFLAME | Breast | Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial) | Jun Masuda | J Immunother Cancer | https://pubmed.ncbi.nlm.nih.gov/37709297/ |
| 2023 | WJOG11318B | MERMAID | Breast | Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: A randomized, open-label phase II trial (MERMAID, WJOG11318B) | Hiroko Masuda | Breast | https://pubmed.ncbi.nlm.nih.gov/37459790/ |
| 2023 | WJOG11218L | APPLE | Thoracic | Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical Trial | Yoshimasa Shiraishi | JAMA Oncol | https://pubmed.ncbi.nlm.nih.gov/38127362/ |
| 2023 | WJOG10818L TR | Thoracic | Alternating Therapy With Osimertinib and Afatinib Blockades EGFR Secondary Mutation in EGFR-Mutant Lung Cancer: A Single-Arm Phase II Trial | Kimio Yonesaka | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/37344331/ | |
| 2023 | LOGIK1603/WJOG9116L | OCEAN | Thoracic | A Phase 2 Single-Arm Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis NSCLC: Results for the First-Line Cohort of the OCEAN Study (LOGIK 1603/WJOG 9116L) | Kazushige Wakuda | JTO Clin Res Rep | https://pubmed.ncbi.nlm.nih.gov/38046380/ |
| 2023 | JCOG0802/WJOG4607L | Thoracic | Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L): a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial | Hisashi Saji | Lancet | https://pubmed.ncbi.nlm.nih.gov/35461558/ | |
| 2022 | WJOG9917B | NEWBEAT | Breast | Safety and efficacy of nivolumab plus bevacizumab, paclitaxel for HER2-negative metastatic breast cancer: Primary results and biomarker data from a phase 2 trial (WJOG9917B) | Yukinori Ozaki | Eur J Cancer | https://pubmed.ncbi.nlm.nih.gov/35728379/ |
| 2022 | WJOG7612GTR | GI | A phase II study to explore iomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in atients with metastatic colorectal cancer (WJOG7612GTR) | Wataru Okamoto | ESMO Open | https://pubmed.ncbi.nlm.nih.gov/36502778/ | |
| 2022 | WJOG6410L | IMPACT | Thoracic | Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT) | Hirohito Tada | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/34726958/ |
| 2022 | WJOG13219G | BRACELET | GI | The Efficacy and Safety of FOLFOXIRI or Doublet plus anti-VEGF therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-institutional Registry-based Study (BRACELET Study) | Keitaro Shimozaki | Clin Colorectal Cancer | https://pubmed.ncbi.nlm.nih.gov/36117091/ |
| 2022 | WJOG10818L | ALT | Thoracic | Alternating Therapy with Osimertinib and Afatinib forTreatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L) | Hidetoshi Hayashi | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/35477147/ |
| 2022 | WJOG10718L | @Be Study | Thoracic | Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study) | Takashi Seto | J Immunother Cancer | https://pubmed.ncbi.nlm.nih.gov/35105689/ |
| 2022 | J-SONIC | Thoracic | Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial | Kohei Otsubo | Eur Respir J | https://pubmed.ncbi.nlm.nih.gov/35361630/ | |
| 2022 | JCOG0804/ WJOG4507L | Thoracic | A single-arm study of sublobar resection for ground-glass opacity dominant peripheral lung cancer | Kenji Suzuki | Interact Cardiovasc Thorac Surg | https://pubmed.ncbi.nlm.nih.gov/25987718/ | |
| 2021 | WJOG9116L | OCEAN | Thoracic | A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L) | Hiroyuki Yamaguchi | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/34419684/ |
| 2021 | WJOG8815L/LPS/LFS | Thoracic | Predicting osimertinib‐treatment outcomes through EGFR mutant‐fraction monitoring in the circulating tumor DNA of EGFR T790M‐positive patients with non‐small cell lung cancer (WJOG8815L) | Kazuko Sakai | Mol Oncol | https://pubmed.ncbi.nlm.nih.gov/33131198/ | |
| 2021 | WJOG8715L | Thoracic | Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M–Mutated Non–Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor: West Japan Oncology Group 8715L Phase 2 Randomized Clinical Trial | Hiroaki Akamatsu | JAMA Oncol | https://pubmed.ncbi.nlm.nih.gov/33410885/ | |
| 2021 | WJOG8515L | Thoracic | A Randomized Phase 2 Study Comparing Nivolumab with Carboplatin-Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L) | Hidetoshi Hayashi | Clin Cancer Res | https://pubmed.ncbi.nlm.nih.gov/34921023/ | |
| 2021 | WJOG7312G | GI | Clinical implications of using both fluoropyrimidine and paclitaxel in patients with severe peritoneal metastasis of gastric cancer: A post-hoc study of JCOG1108/WJOG7312G | Hiroyuki Arai | Cancer Med | https://pubmed.ncbi.nlm.nih.gov/34655175/ | |
| 2021 | WJOG6911L | Thoracic | Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L | Hiroaki Akamatsu | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/34116229/ | |
| 2021 | WJOG13320G | NO LIMIT | GI | An Investigator-Initiated Phase 2 Study of Nivolumab Plus Low-Dose Ipilimumab as First-Line Therapy for Microsatellite Instability—High Advanced Gastric or Esophagogastric Junction Cancer (NO LIMIT, WJOG13320G/CA209-7W7) | Hisato Kawakami | Cancers | https://pubmed.ncbi.nlm.nih.gov/33671871/ |
| 2021 | WJOG13019L | Thoracic | Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L | Shinya Sakata | Cancer Sci | https://pubmed.ncbi.nlm.nih.gov/34704312/ | |
| 2021 | WJOG12819L | Thoracic | A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L) | Masayuki Takeda | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/33612406/ | |
| 2021 | WJOG12519B | Breast | Clinical benefit of treatment after trastuzumab-emtansine for HER2-positive metastatic breast cancer: A real-world multi-centre cohort study in Japan (WJOG12519B) | Takamichi Yokoe | Breast Cancer | https://pubmed.ncbi.nlm.nih.gov/33389616/ | |
| 2021 | WJOG12119L | SQUA | Thoracic | Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non–small-cell Lung Cancer: SQUAT trial (WJOG 12119L) | Akira Hamada | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/34034990/ |
| 2021 | WJOG11619L | DOLPHIN | Thoracic | Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L) | Motoko Tachihara | Cancer Manag Res | https://pubmed.ncbi.nlm.nih.gov/34934361/ |
| 2021 | WJOG11118L | TRAP OLIGO | Thoracic | Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic nonsmall cell lung cancer TRAP OLIGO study (WJOG11118L) | Taichi Miyawaki | BMC Cancer | https://pubmed.ncbi.nlm.nih.gov/34663250/ |
| 2021 | WJOG0105LFS | Thoracic | Effect of Second-generation vs Third-generation Chemotherapy Regimens With Thoracic Radiotherapy on Unresectable Stage III Non–Small-Cell Lung Cancer: 10-Year Follow-up of a WJTOG0105 Phase 3 Randomized Clinical Trial | Yoshitaka Zenke | JAMA Oncol | https://pubmed.ncbi.nlm.nih.gov/33734289/ | |
| 2020 | WJOG9516L | Thoracic | Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study | Kentaro Ito | Eur J Cancer | https://pubmed.ncbi.nlm.nih.gov/33486442/ | |
| 2020 | WJOG8815L/LPS | Thoracic | Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study | Takayuki Takahama | Cancer | https://pubmed.ncbi.nlm.nih.gov/32022929/ | |
| 2020 | WJOG7813L/JCOG1210 | Thoracic | Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non–Small Cell Lung Cancer A Phase 3 Randomized Clinical Trial | Isamu Okamoto | JAMA Oncol | https://pubmed.ncbi.nlm.nih.gov/32163097/ | |
| 2020 | WJOG7512L | Thoracic | A Randomized Phase III Study of Maintenance Therapy with S-1 Plus Best Supportive Care Versus Best Supportive Care After Induction Therapy with Carboplatin Plus S-1 for Advanced or Relapsed Squamous Cell Carcinoma of the Lung (WJOG7512L) | Kaoru Tanaka | Cancer | https://pubmed.ncbi.nlm.nih.gov/32484914/ | |
| 2020 | WJOG7312G | GI | Randomized phase II/III study of 5-fluorouracil/l-leucovorin versus 5-fluorouracil/l-leucovorin plus paclitaxel administered to patients with severe peritoneal metastases of gastric cancer (JCOG1108/WJOG7312G) | Takako Eguchi Nakajima | Gastric Cancer | https://pubmed.ncbi.nlm.nih.gov/32036492/ | |
| 2020 | WJOG7112G | T-ACT | GI | Randomized, Phase II Study of Trastuzumab Beyond Progression in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction Cancer: WJOG7112G (T-ACT Study) | Akitaka Makiyama | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/32208960/ |
| 2020 | WJOG6811B | Breast | A double‐blind, randomized, multicenter phase 3 study of palonosetron vs granisetron combined with dexamethasone and fosaprepitant to prevent chemotherapy‐induced nausea and vomiting in patients with breast cancer receiving anthracycline and cyclophosphamide | Koji Matsumoto | Cancer Medicine | https://pubmed.ncbi.nlm.nih.gov/32168551/ | |
| 2020 | WJOG6510GTR | GI | Biomarker Analysis in A Randomized Phase 2 Study of Panitumumab Versus Cetuximab in Colorectal Cancer (WJOG6510GTR) | Hiroya Taniguchi | J Cancer Sci Clin Ther | https://www.fortunejournals.com/articles/biomarker-analysis-in-a-randomized-phase-2-study-of-panitumumab-versus-cetuximab-in-colorectal-cancer-wjog6510gtr.html | |
| 2020 | WJOG6510G | GI | Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G) | Daisuke Sakai | Eur J Cancer | https://pubmed.ncbi.nlm.nih.gov/32526634/ | |
| 2020 | WJOG6210GSS2 | GI | Early Tumor Shrinkage and Depth of Response in the Second-Line Treatment for KRAS exon2 Wild-Type Metastatic Colorectal Cancer: An Exploratory Analysis of the Randomized Phase 2 Trial Comparing Panitumumab and Bevacizumab in Combination with FOLFIRI (WJOG6210G) | Naoki Izawa | Target Oncol | https://pubmed.ncbi.nlm.nih.gov/32960408/ | |
| 2020 | WJOG5610L | COMPASS | Thoracic | Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: COMPASS (WJOG5610L) | Takashi Seto | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/31880966/ |
| 2020 | WJOG4407GSS2 | GI | Time-dependent discrepancies between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy in patients with metastatic colorectal cancer who received mFOLFOX6 plus bevacizumab: a post-hoc analysis (WJOG4407GSS2) | Yuji Miura | Support Care Cancer | https://pubmed.ncbi.nlm.nih.gov/33200233/ | |
| 2020 | WJOG4407GSS | GI | Morphologic response to chemotherapy containing bevacizumab in patinets with colorectal liver metastases. A post hoc analysis of the WJOG4407G phase III study | Ayumu Hosokawa | Medicine | https://pubmed.ncbi.nlm.nih.gov/32899071/ | |
| 2020 | WJOG11719L | ADJUST | Thoracic | A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group 11719L/ADJUST study) | Ryota Shibaki | Ther Adv Med Oncol | https://pubmed.ncbi.nlm.nih.gov/33613698/ |
| 2020 | WJOG112181L | APPLE | Thoracic | Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer | Yoshimasa Shiraishi | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/32381420/ |
| 2020 | WJOG10617G | P-SELECT | GI | Weekly paclitaxel plus ramucirumab versus weekly nab-paclitaxel plus ramucirumab for unresectable advanced or recurrent gastric cancer with peritoneal dissemination refractory to first-line therapy-the P-SELECT trial (WJOG10617G)-a randomised phase II trial by the West Japan Oncology Group | Kenro Hirata | BMC Cancer | https://pubmed.ncbi.nlm.nih.gov/32532230/ |
| 2020 | WJOG10517G | GI | WJOG10517G: a multicenter Phase II study of mFOLFOX6 in gastric cancer patients with severe peritoneal metastases | Toshiki Masuishi | Future Oncol | https://pubmed.ncbi.nlm.nih.gov/32466683/ | |
| 2020 | WJOG10217L | Thoracic | Propensity Score-Weighted Analysis of Chemotherapy After PD-1 Inhibitors Versus Chemotherapy Alone in Patients With Non-Small Cell Lung Cancer (WJOG10217L) | Ryoji Kato | J Immunother Cancer | https://pubmed.ncbi.nlm.nih.gov/32066647/ | |
| 2020 | WJOG 9116L/LOGIK 1603 | OCEAN | Thoracic | A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L) | Kazushige Wakuda | BMC Cancer | https://pubmed.ncbi.nlm.nih.gov/32357848/ |
| 2020 | ASPECCT/WJOG6510G | GI | Efficacy of Panitumumab and Cetuximab in Patients with Colorectal Cancer Previously Treated with Bevacizumab; a Combined Analysis of Individual Patient Data from ASPECCT and WJOG6510G | Hiroya Taniguchi | Cancers | https://pubmed.ncbi.nlm.nih.gov/32605298/ | |
| 2019 | WJTOG3405 | Thoracic | Final overall survival results of WJTOG3405, a randomized phase III trial comparing gefitinib versus cisplatin with docetaxel as the first-line treatment for patients with stage IIIB/IV or postoperative recurrent EGFR mutation-positive non-small-cell lung cancer | Hiroshige Yoshioka | Ann Oncol | https://pubmed.ncbi.nlm.nih.gov/31553438/ | |
| 2019 | WJOG8715L | Thoracic | Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L) | Hiroaki Akamatsu | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/31085043/ | |
| 2019 | WJOG8114LTR | Thoracic | Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study) | Hiroaki Akamatsu | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/31027689/ | |
| 2019 | WJOG6911L | Thoracic | A phase II study of gefitinib with concurrent thoracic radiotherapy in patients with unresectable, stage III Non-Small Cell Lung Cancer harboring EGFR mutations (WJOG6911L) | Hiroaki Akamatsu | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/30266586/ | |
| 2019 | WJOG4708L | Thoracic | Phase I/II study of intermitted erlotinib in combination with docetaxel in patients with recurrent non-small cell lung cancer (WJOG4708L) | Tatsuo Kimura | Jpn J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/31242302/ | |
| 2019 | WJOG4607L | Thoracic | Comparison of pulmonary segmentectomy and lobectomy: Safety results of a randomized trial | Kenji Suzuki | J Thorac Cardiovasc Surg | https://pubmed.ncbi.nlm.nih.gov/31078312/ | |
| 2018 | WJOG6110B | ELTOP | Breast | A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP | Toshimi Takano | Breast | https://pubmed.ncbi.nlm.nih.gov/29698927/ |
| 2018 | WJOG5308L | Thoracic | Induction Chemo-radiation (50Gy) Followed by Surgery for Stage IIIA-N2 Non-small Cell Lung Cancer | Fumihiro Tanaka | Ann Thorac Surg | https://pubmed.ncbi.nlm.nih.gov/29890150/ | |
| 2018 | WJOG5008L | Thoracic | A randomized phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L | Tomonari Sasaki | Br J Cancer | https://pubmed.ncbi.nlm.nih.gov/30206369/ | |
| 2017 | WJOG7212G | GI | Five-weekly S-1 plus cisplatin with trastuzumab in HER2-positive gastric cancer: a phase II trial and biomarker study (WJOG7212G) | Yuji Miura | Gastric Cancer | https://pubmed.ncbi.nlm.nih.gov/28497176/ | |
| 2017 | PCI | Thoracic | Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial | Toshiaki Takahashi | Lancet Oncol | https://pubmed.ncbi.nlm.nih.gov/28343976/ | |
| 2017 | J-SONIC | Thoracic | Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced NoneSmall-cell Lung Cancer With Idiopathic Pulmonary Fibrosis | Kohei Otsubo | Clin Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/28687482/ | |
| 2016 | WJOG8014LTR | Thoracic | Detection of the T790M mutation of EGFR in plasma of advanced non 13;small cell lung cancer patients with acquired resistance to tyrosine kinase inhibitors (West Japan oncology group 8014LTR study) | Takayuki Takahama | Oncotarget | https://pubmed.ncbi.nlm.nih.gov/27542267/ | |
| 2016 | WJOG6711L | PEOPLE | Thoracic | A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711L (PEOPLE Study) | Takekazu Iwata | Respir Res | https://pubmed.ncbi.nlm.nih.gov/27450274/ |
| 2016 | WJOG6210G | GI | Randomized study of FOLFIRI plus either panitumumab or evacizumab for wild-type KRAS colorectal cancer-WJOG 6210G | Kohei Shitara | Cancer Sci | https://pubmed.ncbi.nlm.nih.gov/27712015/ | |
| 2016 | WJOG5910L | Thoracic | Bevacizumab Beyond Disease Progression After First-Line Treatment With Bevacizumab Plus Chemotherapy in Advanced Nonsquamous Non–Small Cell Lung Cancer (West Japan Oncology Group 5910L): An Open-Label, Randomized, Phase2 Trial | Masayuki Takeda | Cancer | https://pubmed.ncbi.nlm.nih.gov/26828788/ | |
| 2016 | WJOG5108L | Thoracic | Randomized Phase III Study Comparing Gefitinib with Erlotinib in Patients with Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L | Yoshiko Urata | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/27022112/ | |
| 2016 | WJOG4407G | GI | Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G) | Kentaro Yamazaki | Ann Oncol | https://pubmed.ncbi.nlm.nih.gov/27177863/ | |
| 2015 | WJOG5208L | Thoracic | Nedaplatin plus docetaxel versus cipliatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung | Takehito Shukuya | Lancet Oncol | https://pubmed.ncbi.nlm.nih.gov/26522337/ | |
| 2015 | WJOG4207L | Thoracic | A multicenter phase II study of carboplatin and paclitaxel for advanced thymic carcinoma: WJOG4207 L | Fumihiko Hirai | Ann Oncol | https://pubmed.ncbi.nlm.nih.gov/25403584/ | |
| 2015 | WJOG4107 | Thoracic | Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II–IIIA Non–Small Cell Lung Cancer | Yasuo Iwamoto | Clin Cancer Res | https://pubmed.ncbi.nlm.nih.gov/26253869/ | |
| 2015 | JCOG0803/WJOG4307L | Thoracic | Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L | Tetsuya Abe | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/25584004/ | |
| 2014 | WJTOG3806 | Thoracic | A Phase II Study of Zoledronic Acid Combined with Docetaxel for Non–small-cell Lung Cancer: West Japan Oncology Group | Haruyasu Murakami | Cancer Sci | https://pubmed.ncbi.nlm.nih.gov/24837137/ | |
| 2014 | WJTOG0302 | Thoracic | A phase I/II Trial of Irinotecan Plus Amrubicin Supported with G-CSF for Extended Small-cell Lung Cancer | Taishi Harada | Jpn J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/24379211/ | |
| 2014 | WJOG6611LTR | Thoracic | Multiplex genomic profiling of non–small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study | Isamu Okamoto | Oncotarget | https://pubmed.ncbi.nlm.nih.gov/24810493/ | |
| 2013 | WJTOG3605 | LETS | Thoracic | Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study | Hiroshige Yoshioka | Ann Oncol | https://pubmed.ncbi.nlm.nih.gov/23277482/ |
| 2013 | WJOG4007 | Thoracic | Randomized, Open-label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG4007 Trial | Shuichi Hironaka | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/24190112/ | |
| 2013 | WJOG3906L | Thoracic | Histology and Smoking Status Predict Survival of Patients with Advanced Non–Small-Cell Lung CancerResults of West Japan Oncology Group (WJOG) Study 3906L | Yoshihito Kogure | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/23575412/ | |
| 2013 | NEJ 002/WJTOG 3405 | Thoracic | Interstitial Lung Disease Associated with Gefitinib in Japanese Patients with EGFR-mutated Non-small-cell Lung Cancer: Combined Analysis of Two Phase III Trials (NEJ 002 and WJTOG 3405) | Hiroaki Akamatsu | Jpn J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/23585689/ | |
| 2012 | WJTOG9903 | Thoracic | A phase 3 study of induction treatment with concurrent chemorad iotherapy versus chemotherapy before surgery in patients with pathologically confirmed N2 stage IIIA nonsmall cell lung cancer (WJTOG9903) | Nobuyuki Katakami | Cancer | https://pubmed.ncbi.nlm.nih.gov/22674529/ | |
| 2012 | WJTOG3305 | Thoracic | A phase I study of chemoradiotherapy with use of involved-field conformal radiotherapy and accelerated hyperfractionation for stage III non-small cell lung cancer: WJTOG3305 | Takuhito Tada | Int J Radiat Oncol Biol Phys | https://pubmed.ncbi.nlm.nih.gov/22079726/ | |
| 2012 | WJTOG3005 | Thoracic | Phase I Results of Vinorelbine With Concurrent Radiotherapy in Elderly Patients With Unresectable, Locally Advanced Non-Small-Cell Lung Cancer: West Japan Thoracic Oncology Group (WJTOG3005-DI) | Hideyuki Harada | Int J Radiat Oncol Biol Phys | https://pubmed.ncbi.nlm.nih.gov/21621337/ | |
| 2012 | WJTOG2905 | Thoracic | A combination phase I /II study of gemcitabine with carboplatin for previously untreated elderly non-small cell lung cancer; WJTOG 2905 | Takayasu Kurata | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/22306126/ | |
| 2012 | WJTOG0004 | Thoracic | Randomized Phase II Study of Carboplatin-Paclitaxel or Gemcitabine-Vinorelbine in Advanced Nonsmall Cell Lung Cancer and a Performance Status of 2. West Japan Thoracic Oncology Group 0004 | Hiroshi Saito | Am J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/21293243/ | |
| 2012 | WJOG5910L | Thoracic | Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (WJOG5910L) | Masayuki Takeda | BMC Cancer | https://pubmed.ncbi.nlm.nih.gov/22849580/ | |
| 2011 | WJTOG3706 | Thoracic | S-1 plus cisplatin with concurrent radiotherapy for locally advanced non-small cell lung cancer. A muti-institutional phase II trial (West Japan Thoracic Oncology Group 3706) | Yukito Ichinose | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/22052226/ | |
| 2011 | WJTOG0402 | Thoracic | Phase II Study of Gefitinib as a First-line Therapy in Elderly Patients with Lung Adenocarcinoma: WJTOG 0402 | Masahi Kobayashi | Jpn J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/21715363/ | |
| 2010 | WJTOG3605 | Thoracic | Phase III Trial Comparing Oral S-1 Plus Carboplatin With Paclitaxel Plus Carboplatin in Chemotherapy-Naïve Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Oncology Group Study | Isamu Okamoto | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/21079147/ | |
| 2010 | WJTOG3405 | Thoracic | Gefitinib versus cisplatin/docetaxel in patients with non-small cell lung cancer harbouring mutations of epidermal growth factor receptor (WJTOG3405): a randomized phase 3 trial | Tetsutya Mitsudomi | Lancet Oncol | https://pubmed.ncbi.nlm.nih.gov/20022809/ | |
| 2010 | WJTOG0401 | Thoracic | Phase II Trial of Amrubicin for Second-Line Treatment of Advanced Non-small Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG0401) | Hiroyasu Kaneda | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/19884859/ | |
| 2010 | WJTOG0301 | Thoracic | Phase II Study of Sequential Triplet Chemotherapy, Irinotecan and Cisplatin Followed by Amrubicin, in Patientswith Extensive-Stage Small Cell Lung Cancer: West Japan Thoracic Oncology Group Study 0301 | Masashi Kobayashi | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/20479694/ | |
| 2010 | WJTOG0203 | Thoracic | Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in Japanese patients with advanced non-small cell lung cancer: results of a West Japan Thoracic Oncology Group trial (WJTOG0203) | Koji Takeda | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/20038730/ | |
| 2010 | WJTOG0105 | Thoracic | Phase III comparative study of a second generation regimen and third generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Oncology Group WJTOG0105 | Nobuyuki Yamamoto | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/20625120/ | |
| 2009 | WJTOG0202 | Thoracic | A phase I study of topotecan plus carboplatin for relapsed SCLC: WJTOG trial | Takayasu Kurata | J Thorac Oncol | https://pubmed.ncbi.nlm.nih.gov/19325498/ | |
| 2009 | Thoracic | Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations | Satoshi Morita | Clin Cancer Res | https://pubmed.ncbi.nlm.nih.gov/19531624/ | ||
| 2008 | WJTOG3505 | Thoracic | Phase II Study of Combination Therapy with S-1 and Irinotecan for Advanced Non-Small Cell Lung Cancer: West Japan Thoracic Oncology Group 3505 | Isamu Okamoto | Clin Cancer Res | https://pubmed.ncbi.nlm.nih.gov/18698044/ | |
| 2008 | WJTOG0403 | Thoracic | Multicenter prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutation: results of the West Japan Oncology Group trial (WJTOG0403) | Kenji Tamura | Br J Cancer | https://pubmed.ncbi.nlm.nih.gov/18283321/ | |
| 2007 | WJTOG0002 | Thoracic | Phase I/II trial of sequential chemoradiotherapy using a novel hypoxic cell radiosensitizer, doranidazole (PR-350), in patients with locally advanced non-small-cell lung Cancer (WJTOG-0002) | Yasumasa Nishimura | Int J Radiat Oncol Biol Phys | https://pubmed.ncbi.nlm.nih.gov/17512126/ | |
| 2007 | Thoracic | Phase II study of amrubicin, 9-amino-anthracycline, in patients with advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group study | Koji Takeda | Invest New Drugs | https://pubmed.ncbi.nlm.nih.gov/17351748/ | ||
| 2006 | WJTOG9904 | Thoracic | Phase Ⅲ Study of Docetaxel Compared With Vinorelbine in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Results of the West Japan Thoracic Oncology Group Trial (WJTOG9904) | Shinzoh Kudoh | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/16877734/ | |
| 2006 | WJTOG9902 | Thoracic | PhaseⅡStudy of Etoposide and Cisplatin With Concurrent Twice-Daily Thoracic Radiotherapy Followed by Irinotecan and Cisplatin in Patients With Limited-Disease Small-Cell Lung Cancer: West Japan Thoracic Oncology Group 9902 | Hiroshi Saito | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/17114657/ | |
| 2006 | WJTOG0104 | Thoracic | Randomized phase II study of carboplatin/gemcitabine versus vinorelbine/gemcitabine in patients with advanced non-small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) 0104 | Nobuyuki Yamamoto | Cancer | https://pubmed.ncbi.nlm.nih.gov/16804877/ | |
| 2006 | Thoracic | Predictive Factors for Interstitial Lung Disease, Antitumor Response and Survival in Non-Small-Cell Lung Cancer Patients Treated With Gefitinib | Masahiko Ando | J Clin Oncol | https://pubmed.ncbi.nlm.nih.gov/16735708/ | ||
| 2005 | Thoracic | Irinotecan and etoposide for previously untreated extensive-disease small cell lung cancer: A phase II trial of West Japan Thoracic Oncology Group | Shinzoh Kudoh | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/16022921/ | ||
| 2004 | WJTOG9908 | Thoracic | Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB-IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908 | Nobuyuki Katakami | Lung Cancer | https://pubmed.ncbi.nlm.nih.gov/14698543/ | |
| 2004 | WJTOG9803 | Thoracic | Randomised phase II study of docetaxel/cisplatin vs docetaxel/irinotecan in advanced non-small-cell lung cancer: a West Japan Thoracic Oncology Group Study (WJTOG9803) | Nobuyuki Yamamoto | Br J Cancer | https://pubmed.ncbi.nlm.nih.gov/14710212/ |
